HAEMONETICS CORP/MASS (HAE) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:HAE - US4050241003 - Common Stock
74 USD
-1.73 (-2.28%)
74 USD
0 (0%)
Overall HAE gets a fundamental rating of 5 out of 10. We evaluated HAE against 185 industry peers in the Health Care Equipment & Supplies industry. While HAE has a great profitability rating, there are some minor concerns on its financial health. HAE may be a bit undervalued, certainly considering the very reasonable score on growth
1. Profitability
1.1 Basic Checks
- HAE had positive earnings in the past year.
- HAE had a positive operating cash flow in the past year.
- Each year in the past 5 years HAE has been profitable.
- In the past 5 years HAE always reported a positive cash flow from operatings.
1.2 Ratios
- Looking at the Return On Assets, with a value of 6.89%, HAE belongs to the top of the industry, outperforming 87.57% of the companies in the same industry.
- HAE's Return On Equity of 19.81% is amongst the best of the industry. HAE outperforms 94.05% of its industry peers.
- HAE's Return On Invested Capital of 10.48% is amongst the best of the industry. HAE outperforms 89.73% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for HAE is in line with the industry average of 8.84%.
- The last Return On Invested Capital (10.48%) for HAE is above the 3 year average (8.96%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.89% | ||
| ROE | 19.81% | ||
| ROIC | 10.48% |
ROA(3y)6.05%
ROA(5y)4.97%
ROE(3y)15.59%
ROE(5y)12.69%
ROIC(3y)8.96%
ROIC(5y)7.22%
1.3 Margins
- With an excellent Profit Margin value of 12.67%, HAE belongs to the best of the industry, outperforming 88.65% of the companies in the same industry.
- HAE's Profit Margin has improved in the last couple of years.
- HAE has a Operating Margin of 19.11%. This is amongst the best in the industry. HAE outperforms 91.89% of its industry peers.
- In the last couple of years the Operating Margin of HAE has remained more or less at the same level.
- HAE has a Gross Margin of 58.46%. This is comparable to the rest of the industry: HAE outperforms 58.38% of its industry peers.
- HAE's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.11% | ||
| PM (TTM) | 12.67% | ||
| GM | 58.46% |
OM growth 3Y21.18%
OM growth 5Y0.48%
PM growth 3Y41.28%
PM growth 5Y9.75%
GM growth 3Y1.97%
GM growth 5Y2.6%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so HAE is still creating some value.
- The number of shares outstanding for HAE has been reduced compared to 1 year ago.
- The number of shares outstanding for HAE has been reduced compared to 5 years ago.
- HAE has a worse debt/assets ratio than last year.
2.2 Solvency
- HAE has an Altman-Z score of 2.59. This is not the best score and indicates that HAE is in the grey zone with still only limited risk for bankruptcy at the moment.
- With a decent Altman-Z score value of 2.59, HAE is doing good in the industry, outperforming 68.11% of the companies in the same industry.
- The Debt to FCF ratio of HAE is 5.76, which is a neutral value as it means it would take HAE, 5.76 years of fcf income to pay off all of its debts.
- HAE has a better Debt to FCF ratio (5.76) than 77.84% of its industry peers.
- A Debt/Equity ratio of 1.08 is on the high side and indicates that HAE has dependencies on debt financing.
- HAE's Debt to Equity ratio of 1.08 is on the low side compared to the rest of the industry. HAE is outperformed by 76.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.08 | ||
| Debt/FCF | 5.76 | ||
| Altman-Z | 2.59 |
ROIC/WACC1.17
WACC8.96%
2.3 Liquidity
- A Current Ratio of 1.64 indicates that HAE should not have too much problems paying its short term obligations.
- HAE has a worse Current ratio (1.64) than 71.35% of its industry peers.
- HAE has a Quick Ratio of 1.03. This is a normal value and indicates that HAE is financially healthy and should not expect problems in meeting its short term obligations.
- HAE has a worse Quick ratio (1.03) than 74.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.64 | ||
| Quick Ratio | 1.03 |
3. Growth
3.1 Past
- HAE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.65%, which is quite good.
- Measured over the past 5 years, HAE shows a small growth in Earnings Per Share. The EPS has been growing by 6.66% on average per year.
- The Revenue has decreased by -2.45% in the past year.
- The Revenue has been growing slightly by 6.60% on average over the past years.
EPS 1Y (TTM)17.65%
EPS 3Y20.84%
EPS 5Y6.66%
EPS Q2Q%13.39%
Revenue 1Y (TTM)-2.45%
Revenue growth 3Y11.07%
Revenue growth 5Y6.6%
Sales Q2Q%-5.27%
3.2 Future
- Based on estimates for the next years, HAE will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.57% on average per year.
- Based on estimates for the next years, HAE will show a small growth in Revenue. The Revenue will grow by 3.31% on average per year.
EPS Next Y8.59%
EPS Next 2Y9.96%
EPS Next 3Y10.57%
EPS Next 5YN/A
Revenue Next Year-3.06%
Revenue Next 2Y1.37%
Revenue Next 3Y3.31%
Revenue Next 5YN/A
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 15.42, the valuation of HAE can be described as correct.
- Based on the Price/Earnings ratio, HAE is valued cheaper than 88.65% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.54, HAE is valued a bit cheaper.
- With a Price/Forward Earnings ratio of 13.39, HAE is valued correctly.
- Based on the Price/Forward Earnings ratio, HAE is valued cheaply inside the industry as 90.81% of the companies are valued more expensively.
- The average S&P500 Price/Forward Earnings ratio is at 24.31. HAE is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.42 | ||
| Fwd PE | 13.39 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HAE indicates a rather cheap valuation: HAE is cheaper than 87.57% of the companies listed in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of HAE indicates a rather cheap valuation: HAE is cheaper than 94.05% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.3 | ||
| EV/EBITDA | 12.16 |
4.3 Compensation for Growth
- HAE's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- The excellent profitability rating of HAE may justify a higher PE ratio.
PEG (NY)1.79
PEG (5Y)2.31
EPS Next 2Y9.96%
EPS Next 3Y10.57%
5. Dividend
5.1 Amount
- No dividends for HAE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
74
-1.73 (-2.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)02-04 2026-02-04/bmo
Inst Owners113.47%
Inst Owner Change-0.22%
Ins Owners1.17%
Ins Owner Change1.67%
Market Cap3.46B
Revenue(TTM)1.33B
Net Income(TTM)168.19M
Analysts78.67
Price Target93.53 (26.39%)
Short Float %7.33%
Short Ratio3.83
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.23%
Min EPS beat(2)7.2%
Max EPS beat(2)13.26%
EPS beat(4)4
Avg EPS beat(4)5.44%
Min EPS beat(4)0.62%
Max EPS beat(4)13.26%
EPS beat(8)7
Avg EPS beat(8)4.36%
EPS beat(12)11
Avg EPS beat(12)8.38%
EPS beat(16)15
Avg EPS beat(16)9.71%
Revenue beat(2)2
Avg Revenue beat(2)4.31%
Min Revenue beat(2)4.07%
Max Revenue beat(2)4.55%
Revenue beat(4)2
Avg Revenue beat(4)1.44%
Min Revenue beat(4)-2.22%
Max Revenue beat(4)4.55%
Revenue beat(8)4
Avg Revenue beat(8)1.51%
Revenue beat(12)8
Avg Revenue beat(12)1.89%
Revenue beat(16)11
Avg Revenue beat(16)2.17%
PT rev (1m)8.46%
PT rev (3m)14.2%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.36%
EPS NY rev (1m)0%
EPS NY rev (3m)1.83%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.9%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.76%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.42 | ||
| Fwd PE | 13.39 | ||
| P/S | 2.61 | ||
| P/FCF | 16.3 | ||
| P/OCF | 11.98 | ||
| P/B | 4.08 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.16 |
EPS(TTM)4.8
EY6.49%
EPS(NY)5.53
Fwd EY7.47%
FCF(TTM)4.54
FCFY6.14%
OCF(TTM)6.17
OCFY8.34%
SpS28.37
BVpS18.14
TBVpS-3.96
PEG (NY)1.79
PEG (5Y)2.31
Graham Number44.26
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.89% | ||
| ROE | 19.81% | ||
| ROCE | 13.4% | ||
| ROIC | 10.48% | ||
| ROICexc | 12.43% | ||
| ROICexgc | 35.27% | ||
| OM | 19.11% | ||
| PM (TTM) | 12.67% | ||
| GM | 58.46% | ||
| FCFM | 16.01% |
ROA(3y)6.05%
ROA(5y)4.97%
ROE(3y)15.59%
ROE(5y)12.69%
ROIC(3y)8.96%
ROIC(5y)7.22%
ROICexc(3y)10.46%
ROICexc(5y)8.47%
ROICexgc(3y)26.78%
ROICexgc(5y)22.33%
ROCE(3y)11.45%
ROCE(5y)9.23%
ROICexgc growth 3Y22.36%
ROICexgc growth 5Y7.33%
ROICexc growth 3Y21.7%
ROICexc growth 5Y-5.09%
OM growth 3Y21.18%
OM growth 5Y0.48%
PM growth 3Y41.28%
PM growth 5Y9.75%
GM growth 3Y1.97%
GM growth 5Y2.6%
F-Score8
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.08 | ||
| Debt/FCF | 5.76 | ||
| Debt/EBITDA | 2.5 | ||
| Cap/Depr | 66.93% | ||
| Cap/Sales | 5.76% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 78.54% | ||
| Profit Quality | 126.39% | ||
| Current Ratio | 1.64 | ||
| Quick Ratio | 1.03 | ||
| Altman-Z | 2.59 |
F-Score8
WACC8.96%
ROIC/WACC1.17
Cap/Depr(3y)79.52%
Cap/Depr(5y)76.24%
Cap/Sales(3y)6.31%
Cap/Sales(5y)6.58%
Profit Quality(3y)103.91%
Profit Quality(5y)115.34%
High Growth Momentum
Growth
EPS 1Y (TTM)17.65%
EPS 3Y20.84%
EPS 5Y6.66%
EPS Q2Q%13.39%
EPS Next Y8.59%
EPS Next 2Y9.96%
EPS Next 3Y10.57%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.45%
Revenue growth 3Y11.07%
Revenue growth 5Y6.6%
Sales Q2Q%-5.27%
Revenue Next Year-3.06%
Revenue Next 2Y1.37%
Revenue Next 3Y3.31%
Revenue Next 5YN/A
EBIT growth 1Y18%
EBIT growth 3Y34.59%
EBIT growth 5Y7.12%
EBIT Next Year34.68%
EBIT Next 3Y14.43%
EBIT Next 5YN/A
FCF growth 1Y6.71%
FCF growth 3Y16.98%
FCF growth 5Y2.09%
OCF growth 1Y10.19%
OCF growth 3Y1.79%
OCF growth 5Y2.81%
HAEMONETICS CORP/MASS / HAE FAQ
What is the ChartMill fundamental rating of HAEMONETICS CORP/MASS (HAE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to HAE.
Can you provide the valuation status for HAEMONETICS CORP/MASS?
ChartMill assigns a valuation rating of 7 / 10 to HAEMONETICS CORP/MASS (HAE). This can be considered as Undervalued.
What is the profitability of HAE stock?
HAEMONETICS CORP/MASS (HAE) has a profitability rating of 8 / 10.
Can you provide the expected EPS growth for HAE stock?
The Earnings per Share (EPS) of HAEMONETICS CORP/MASS (HAE) is expected to grow by 8.59% in the next year.